Sébastien Plouffe
Patrimonio netto: 538 200 $ in data 31/07/2026
Patrimonio netto: 538 200 $ in data 31/07/2026
Sébastien Plouffe is the founder of Sediamek, Inc., founded in 2006, serving as President & Chief Executive Officer.
Mr. Plouffe is the founder of Defence Therapeutics Inc, founded in 2017, serving as Executive Chairman.
Mr. Plouffe is also the founder of Chevalier Resources, Inc...
Mr. Plouffe currently serves as Director at Bullion Gold Discoveries Corp.
Former positions include President, Chief Executive Officer & Director at Affinor Growers, Inc. (2014–2015); Director & Vice President-Public Relations at Vanstar Mining Resources, Inc. (2019–2020);.
Secretary at X-Terra Resources Corp.
(2007–2010); Head-Investor Relations at Anticus International Corp.; Vice President-Finance at Ximen Mining Corp.; Vice President at BMO Nesbitt Burns, Inc.; and Vice President at Canaccord Genuity Corp.
(Investment Management).
Education includes an undergraduate degree from HEC Montréal, conferred in 1994.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/08/2026 | 1.800.000 ( 2,38% ) | 538 200 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| DEFENCE THERAPEUTICS INC. | Fondatore | 18/07/2017 |
| BULLION GOLD DISCOVERIES CORP. | Direttore/Membro del Consiglio | - |
Sediamek, Inc. | Amministratore Delegato | 01/01/2006 |
| Società | Posizione | Fine |
|---|---|---|
| VANSTAR MINING RESOURCES INC. | Direttore/Membro del Consiglio | 18/08/2020 |
| AFFINOR GROWERS INC. | Amministratore Delegato | 02/10/2015 |
Canaccord Genuity Corp. (Investment Management)
Canaccord Genuity Corp. (Investment Management) Investment ManagersFinance Profile Unavailable. | Corporate Officer/Principal | - |
BMO Nesbitt Burns, Inc.
BMO Nesbitt Burns, Inc. Financial ConglomeratesFinance Provides investment and financial advisory services | Corporate Officer/Principal | - |
Chevalier Resources, Inc.
Chevalier Resources, Inc. Other Metals/MineralsNon-Energy Minerals Mines for copper and cobalt | Fondatore | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 12 |
|---|---|
X-Terra Resources Corp.
X-Terra Resources Corp. Other Metals/MineralsNon-Energy Minerals Acquires, explores and develops mining properties | Non-Energy Minerals |
Affinor Growers, Inc.
Affinor Growers, Inc. Agricultural Commodities/MillingProcess Industries Grows and distributes medical marijuana | Process Industries |
Anticus International Corp.
Anticus International Corp. Food: Major DiversifiedConsumer Non-Durables Operates as a development stage company with interest to continue its world-wide license to convert waste materials from beer, soft drink and cheese manufacturers into yeast | Consumer Non-Durables |
Bullion Gold Resources Corp.
Bullion Gold Resources Corp. Precious MetalsNon-Energy Minerals Engages in the acquisition and exploration of mineral properties | Non-Energy Minerals |
Ximen Mining Corp.
Ximen Mining Corp. Precious MetalsNon-Energy Minerals Engages in exploration and development of mineral properties | Non-Energy Minerals |
Vanstar Mining Resources, Inc.
Vanstar Mining Resources, Inc. Precious MetalsNon-Energy Minerals Engages in the acquisition, exploration and development of mining & metal properties | Non-Energy Minerals |
BMO Nesbitt Burns, Inc.
BMO Nesbitt Burns, Inc. Financial ConglomeratesFinance Provides investment and financial advisory services | Finance |
HEC Montréal
HEC Montréal Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chevalier Resources, Inc.
Chevalier Resources, Inc. Other Metals/MineralsNon-Energy Minerals Mines for copper and cobalt | Non-Energy Minerals |
Canaccord Genuity Corp. (Investment Management)
Canaccord Genuity Corp. (Investment Management) Investment ManagersFinance Profile Unavailable. | Finance |
Sediamek, Inc. | |
Defence Therapeutics Inc
Defence Therapeutics Inc Pharmaceuticals: MajorHealth Technology Engages in the research and development of anti-body drug conjugates | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale